Dyslipidaemia is instrumental in the progression of diabetic neuropathy
Document Actions
There is mounting epidemiological evidence that dyslipidaemia is associated with microangiopathy in target-organs for diabetic complications. The study was designed to evaluate mechanisms underlying diabetic neuropathy (DN) progression based on sural nerve morphometry indices obtained from two randomized placebo-controlled clinical trials. A loss of ≥500 fibers/mm2 in sural nerve myelinated fiber density (MFD) over 52 weeks was defined as progressing DN and a MDF loss of ≤100 fibers/mm2 during the same time interval defined non-progressing DN. At 52 weeks, the progressing cohort exhibited a 25% decrease from baseline in MFD whereas the non-progressing cohort remained unchanged. Active treatment, diabetes duration, age and body mass index did not affect MDF loss while elevated triglycerides and decreased peroneal motor nerve conduction velocity at baseline significantly correlated with MDF loss at 52 weeks. These data support the evolving concept that dyslipidaemia is instrumental in diabetic neuropathy progression.
Abstract
